Molecular genetic basis for fluoroquinolone-induced retinal degeneration in cats

Pharmacogenetics and Genomics

Volumn 21, Issue 2, 2011, Pages 66-75

  Ramirez, Christina J ^a   Minch, Jonathan D ^a   Gay, John M ^a   Lahmers, Sunshine M ^a   Guerra, Dan J ^b   Haldorson, Gary J ^a   Schneider, Terri ^a   Mealey, Katrina L ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Program in Neuroscience   (United States)

Author keywords

ABCG2; enrofloxacin; feline; fluoroquinolone; phototoxicity; retina; retinal degeneration

Indexed keywords

AMINO ACID; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; CIPROFLOXACIN; COMPLEMENTARY DNA; ENROFLOXACIN; MITOXANTRONE; PRAZOSIN; QUINOLONE DERIVATIVE; REACTIVE OXYGEN METABOLITE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLINDNESS; BLOOD RETINA BARRIER; CAT; CELL MEMBRANE; CELL STRAIN HEK293; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG INDUCED DISEASE; EMBRYO; EXPRESSION VECTOR; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; MAMMAL; MOLECULAR GENETICS; NONHUMAN; PHOTOREACTIVITY; PHOTOTOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA DEGENERATION; WESTERN BLOTTING;

FELIDAE; MAMMALIA;

EID: 78751627527     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283425f44     Document Type: Article

References (35)

1. Crispin SM, Gould DJ, Carter WJ, Lowe RC. Idiosyncratic reaction to enrofloxacin in cats. Vet Rec 2002; 150:555-556.
2. Ford MM, Dubielzig RR, Giuliano EA, Moore CP, Narfstrom KL. Ocular and systemic manifestations after oral administration of a high dose of enrofloxacin in cats. Am J Vet Res 2007; 68:190-202.
3. Gelatt KN, van der Woerdt A, Ketring KL, Andrew SE, Brooks DE, Biros DJ, et al. Enrofloxacin-associated retinal degeneration in cats. Vet Ophthalmol 2001; 4:99-106.
4. Watson PM. Idiosyncratic reaction to enrofloxacin in cats. Vet Rec 2002; 150:556.
5. Wiebe V, Hamilton P. Fluoroquinolone-induced retinal degeneration in cats. J Am Vet Med Assoc 2002; 221:1568-1571.
6. Mehlhorn AJ, Brown DA. Safety concerns with fluoroquinolones. Ann Pharmacother 2007; 41:1859-1866.
7. Agrawal N, Ray RS, Farooq M, Pant AB, Hans RK. Photosensitizing potential of ciprofloxacin at ambient level of UV radiation. Photochem Photobiol 2007; 83:1226-1236.
8. Vassileva SG, Mateev G, Parish LC. Antimicrobial photosensitive reactions. Arch Intern Med 1998; 158:1993-2000.
9. Marrot L, Belaidi JP, Jones C, Perez P, Riou L, Sarasin A, Meunier JR. Molecular responses to photogenotoxic stress induced by the antibiotic lomefloxacin in human skin cells: from DNA damage to apoptosis. J Invest Dermatol 2003; 121:596-606.
10. Roberts JE. Ocular phototoxicity. J Photochem Photobiol B 2001; 64:136-143.
11. Hornof M, Toropainen E, Urtti A. Cell culture models of the ocular barriers. Eur J Pharm Biopharm 2005; 60:207-225.
12. Hosoya K, Makihara A, Tsujikawa Y, Yoneyama D, Mori S, Terasaki T, et al. Roles of inner blood-retinal barrier organic anion transporter 3 in the vitreous/retina-to-blood efflux transport of p-aminohippuric acid, benzylpenicillin, and 6-mercaptopurine. J Pharmacol Exp Ther 2009; 329:87-93.
13. Alvarez AI, Perez M, Prieto JG, Molina AJ, Real R, Merino G. Fluoroquinolone efflux mediated by ABC transporters. J Pharm Sci 2008; 97:3483-3493.
14. Jonker JW, Merino G, Musters S, van Herwaarden AE, Bolscher E, Wagenaar E, et al. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med 2005; 11:127-129.
15. Cusatis G, Sparreboom A. Pharmacogenomic importance of ABCG2. Pharmacogenomics 2008; 9:1005-1009.
16. Merino G, Alvarez AI, Pulido MM, Molina AJ, Schinkel AH, Prieto JG. Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos 2006; 34:690-695.
17. Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005; 204:216-237.
18. Cha PC, Mushiroda T, Zembutsu H, Harada H, Shinoda N, Kawamoto S, et al. Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression. J Hum Genet 2009; 54:572-580.
19. Jordan JP, Hand CM, Markowitz RS, Black P. Test for chemotherapeutic sensitivity of cerebral gliomas: use of colorimetric MTT assay. J Neurooncol 1992; 14:19-35.
20. Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, van de Laar A, et al. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 2001; 61:6635-6639.
21. Robey RW, Honjo Y, van de Laar A, Miyake K, Regis JT, Litman T, Bates SE. A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochim Biophys Acta 2001; 1512:171-182.
22. Ozvegy-Laczka C, Koblos G, Sarkadi B, Varadi A. Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition. Biochim Biophys Acta 2005; 1668:53-63.
23. Maekawa K, Itoda M, Sai K, Saito Y, Kaniwa N, Shirao K, et al. Genetic variation and haplotype structure of the ABC transporter gene ABCG2 in a Japanese population. Drug Metab Pharmacokinet 2006; 21:109-121.
24. Tamura A, Wakabayashi K, Onishi Y, Nakagawa H, Tsuji M, Matsuda Y, Ishikawa T. Genetic polymorphisms of human ABC transporter ABCG2: development of the standard method for functional validation of SNPs by using the Flp recombinase system. J Exp Ther Oncol 2006; 6:1-11.
25. Morisaki K, Robey RW, Ozvegy-Laczka C, Honjo Y, Polgar O, Steadman K, et al. Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol 2005; 56:161-172.
26. Robey RW, To KK, Polgar O, Dohse M, Fetsch P, Dean M, Bates SE. ABCG2: a perspective. Adv Drug Deliv Rev 2009; 61:3-13.
27. Merino G, Jonker JW, Wagenaar E, van Herwaarden AE, Schinkel AH. The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol 2005; 67:1758-1764.
28. Henrich CJ, Robey RW, Bokesch HR, Bates SE, Shukla S, Ambudkar SV, et al. New inhibitors of ABCG2 identified by high-throughput screening. Mol Cancer Ther 2007; 6:3271-3278.
29. Zhang Y, Byun Y, Ren YR, Liu JO, Laterra J, Pomper MG. Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay. Cancer Res 2009; 69:5867-5875.
30. Cullen M, Baijal S. Prevention of febrile neutropenia: use of prophylactic antibiotics. Br J Cancer 2009; 101 (Suppl 1):S11-S14.
31. Marti FM, Cullen MH, Roila F. Management of febrile neutropenia: ESMO clinical recommendations. Ann Oncol 2009; 20 (Suppl 4):166-169.
32. Albarellos GA, Landoni MF. Current concepts on the use of antimicrobials in cats. Vet J 2009; 180:304-316.
33. Lascelles BD, Court MH, Hardie EM, Robertson SA. Nonsteroidal anti-inflammatory drugs in cats: a review. Vet Anaesth Analg 2007; 34:228-250.
34. Court MH, Greenblatt DJ. Molecular basis for deficient acetaminophen glucuronidation in cats. An interspecies comparison of enzyme kinetics in liver microsomes. Biochem Pharmacol 1997; 53:1041-1047.
35. Zamek-Gliszczynski MJ, Nezasa K, Tian X, Kalvass JC, Patel NJ, Raub TJ, Brouwer KL. The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice. Mol Pharmacol 2006; 70:2127-2133.